Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis
Luspatercept has emerged as a novel therapy for anemia in transfusion-dependent (TD) lower-risk
patient
Azacitidine as therapy for VEXAS syndrome
How should patients with VEXAS (an acronym for vacuoles [in myeloid and erythroid precursors], E1 enzyme, X-linked, autoinflammatory, somatic) syndrome be treated? Until now, we have only had case reports and small series to guide us.
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Abstract
What is Aplastic Anemia? From the 2025 Boston Patient and Family Conference
High Risk MDS from the 2025 Boston Patient and Family Conference
In this recording, Dr. Jacqueline Garcia discusses the diagnosis of high risk MDS and the treatment options available to patients.
MDS to MPN Overlap from the 2025 Boston Patient and Family Conference
In this recording, Dr. Richard Stone discusses the diagnosis of MDS/MPN overlap and the treatment options available to patients.
Low Risk MDS from the 2025 Boston Patient and Family Conference
In this recording, Dr. Andrew Brunner discusses the diagnosis of low risk MDS overlap and the treatment options available to patients.
Jeremy A. Meier, MD, PhD
Meier, Jeremy
Assistant Professor of Medicine
University of North Carolina at Chapel Hill School of Medicine
As a physician scientist Dr. Meier always had a passion for integrating patient care with research dedicated to improving cancer treatments. Clinically He is specialized in the management of patients with hematologic malignancies who are undergoing stem cell transplantation or receiving other cellular therapies, like CAR T cells. Dr. Meier research is focused on better understanding how to fully engage the immune system in its fight against cancer.
Brandi Reeves, MD
Reeves, Brandi
Associate Professor of Medicine
University of North Carolina at Chapel Hill School of Medicine
Jose C. Martinez, MD, PhD
Martinez, Jose
Assistant Professor of Medicine
University of North Carolina at Chapel Hill School of Medicine
I am a physician-scientist who sees patients in clinic with disorders of clonal hematopoiesis and myeloid cancers, including